Edition:
United Kingdom

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

72.50CHF
23 May 2018
Change (% chg)

CHF-0.85 (-1.16%)
Prev Close
CHF73.35
Open
CHF73.20
Day's High
CHF73.20
Day's Low
CHF72.05
Volume
51,378
Avg. Vol
65,812
52-wk High
CHF87.10
52-wk Low
CHF63.75

Chart for

About

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant... (more)

Overall

Beta: 1.31
Market Cap(Mil.): CHF947.87
Shares Outstanding(Mil.): 11.86
Dividend: --
Yield (%): --

Financials

  BSLN.S Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -4.21 -- --
ROI: -17.70 1.57 14.38
ROE: -- 2.43 16.07

BRIEF-Basilea Pharmaceutica Appoints Gerrit Hauck As CTO

* GERRIT HAUCK APPOINTED AS CHIEF TECHNOLOGY OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

27 Apr 2018

BRIEF-Basilea: Start Of Clinical Phase 3 Study In Japan

* BASILEA REPORTS START OF CLINICAL PHASE 3 STUDY IN JAPAN BY ASAHI KASEI PHARMA WITH ANTIFUNGAL ISAVUCONAZOLE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

18 Apr 2018

BRIEF-Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib

* ARQULE AND BASILEA ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DERAZANTINIB IN THE US, EU, JAPAN AND REST OF WORLD EXCLUDING GREATER CHINA

17 Apr 2018

BRIEF-Basilea Pharmaceutica Licenses Late-Stage Oncology Drug Candidate Derazantinib

* LICENSES LATE-STAGE ONCOLOGY DRUG CANDIDATE DERAZANTINIB FROM ARQULE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

17 Apr 2018

BRIEF-Basilea Pharmaceutica: Partner Avir Pharma Launches Basilea's Ceftobiprole In Canada

* ITS PARTNER AVIR PHARMA INC HAS LAUNCHED BASILEA'S HOSPITAL ANTIBIOTIC ZEVTERA (CEFTOBIPROLE) IN CANADA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

09 Apr 2018

BRIEF-Basilea Pharmaceutica FY Operating Loss At CHF 14.1 million

* FY ‍54% INCREASE IN TOTAL REVENUE, AMOUNTING TO CHF 101.5 MILLION​

27 Feb 2018

BRIEF-Basilea Pharmaceutica Reports Clinical Phase 3 Study Start With Antibiotic Ceftobiprole In Skin Infections

* REPORTS CLINICAL PHASE 3 STUDY START WITH ANTIBIOTIC CEFTOBIPROLE IN SKIN INFECTIONS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

23 Feb 2018

BRIEF-Basilea Appoints David Veitch As New CEO

* BASILEA'S CEO RONALD SCOTT WILL RETIRE. CHIEF COMMERCIAL OFFICER DAVID VEITCH NAMED AS SUCCESSOR. CHANGES IN THE BOARD OF DIRECTORS

21 Feb 2018

BRIEF-Basilea starts clinical phase 1 study in collaboration with U.S. Adult Brain Tumor Consortium ​

* ‍INITIATION OF A PHASE 1 STUDY CONDUCTED UNDER ITS CLINICAL STUDY AGREEMENT WITH ADULT BRAIN TUMOR CONSORTIUM IN U.S.​

03 Jan 2018

BRIEF-Basilea: Ceftobiprole Gets QIDP Designation From U.S. FDA

* BASILEA REPORTS THAT CEFTOBIPROLE RECEIVED QIDP DESIGNATION FROM U.S. FDA FOR THE TREATMENT OF STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

21 Dec 2017

Earnings vs. Estimates